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S U M M A R Y
Objectives: The risk of developing Lyme borreliosis (LB) from Borrelia burgdorferi sensu lato (Bb)-infected
ticks in Sweden is largely unknown. In the current study, we investigated the prevalence of Bb in ticks
that had bitten humans and the risk of developing LB from Bb-infected ticks.
Methods: Health questionnaires, blood samples, and ticks were collected from 394 tick-bitten study
subjects in the County of O¨stergo¨tland, Sweden, at the time of the tick bite. Questionnaires and blood
samples were also collected 3 months later. Ticks were screened for Bb DNA with PCR, while sera were
analyzed for antibodies against Bb using two ELISA assays. Seroconversion, i.e., an at least two-fold
increase in anti-Bb antibodies after 3 months, was conﬁrmed using a Strip-Immunoassay.
Results: Seventy-ﬁve of 397 ticks collected from the study subjects were determined to be Bb-positive.
Sixty-four of the tick-bitten subjects had been bitten by Bb-infected ticks. Four of them showed
seroconversion andwere therefore considered to have an active Bb infection. None of these four subjects
had sought health care due to symptoms, but one reported symptoms.
Conclusions: Our data suggest that the risk of developing LB after being bitten by a Bb-infected tick is
low, and asymptomatic Bb infections appear to be more frequent than symptomatic infections.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The spirochete Borrelia burgdorferi sensu lato (Bb) is the
causative agent of the tick-borne disease Lyme borreliosis (LB).1
At least four species of Bb – Borrelia burgdorferi sensu stricto,
Borrelia garinii, Borrelia afzelii,2 and the newly described Borrelia
spielmanii3 – are known to be pathogenic to humans. The disease is
nationally notiﬁable in the USA, Japan, and in several European
countries, e.g., Estonia, Latvia, Lithuania, Croatia, Czech Republic,
Italy, Portugal, Slovenia, and Scotland.4 The highest frequencies of
LB in Europe are reported from Austria, Germany, Slovenia, and
Sweden, while the highest frequencies in the USA are reported
from the northeastern and upper midwest states.1,5 The distribu-
tion of LB is heterogeneous, with hyperendemic areas where the
incidence is over 100 annual clinical LB infections per 100 000
inhabitants, such as the A˚land Islands with 2000/100 000/year6
and the Swedish county of Blekinge with an incidence of 464/100
000/year.7 The incidence rate of LB in Sweden has not been fully* Corresponding author.
E-mail address: christina.ekerfelt@liu.se (C. Ekerfelt).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.10.006investigated. Two previous studies have investigated the annual
incidence of LB in the southeastern county of Blekinge (464/100
000 inhabitants)7 and in seven southern counties (69/100 000
inhabitants).8
The clinical manifestations of the disease can be divided into
three stages: early localized infection occurring in the skin and
manifested by the development of erythema migrans or lympho-
cytoma; early disseminated infection usually manifested by
neurological (neuroborreliosis) or muscoskeletal symptoms (Lyme
arthritis); and late disseminated infection in untreated patients
who have developed acrodermatitis chronica atrophicans, chronic
neuroborreliosis, or Lyme arthritis. In addition, the clinical
outcome of the infection differs between individuals. Individuals
may have an infection that is principally asymptomatic,8–10 or a
subacute infection deﬁned as symptoms lasting less than 6
months, or symptoms lasting more than 6 months despite well-
recognized antibiotic treatment, i.e., LB with persistent symptoms
post-treatment.11–15
The risk of developing LB from a Bb-infected tick has not been
well-studied in Sweden, although several studies in other
countries have addressed this issue,16–20 and LB is the most
commonly reported arthropod-borne disease in both the USA andses. Published by Elsevier Ltd. All rights reserved.
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individuals who have no experience of symptoms possibly
associated with LB.10,21 This may indicate that the immune system
eradicates the spirochete rapidly and efﬁciently. Thus, asymptom-
atic infections, where symptoms associated with LB are absent,
could be frequent after Bb infection. However, to our knowledge,
this has not been thoroughly investigated. Nadelman et al.18 have
previously shown that 3.2% of healthy newly tick-bitten control
subjects in an antibiotic prophylaxis study performed in an
American hyperendemic area, developed erythema migrans during
the 6-week study period. Surprisingly, none of the study control
subjects appeared to have an asymptomatic Bb infection. However,
B. burgdorferi sensu stricto is the only human pathogenic strain of
Bb in the USA. Therefore, the disease outcome of healthy newly
tick-bitten individuals bitten by infected ticks in Europe, where B.
afzelii and B. garinii are prevalent, needs to be further investigated
in order to study the risk of developing LB and the occurrence of
asymptomatic infections in Europe. Therefore, we proposed to
follow tick-bitten individuals for a period of 3months after the tick
bite, in order to study the rate of infection and the clinical outcome.
Expanding our knowledge of the risks of developing LB is also
important in order to understand the different disease outcomes.
The aim of this study was to evaluate the risk of developing LB
after being bitten by a Bb-infected tick. We also wanted to
investigate if asymptomatic Bb infections occur, by determining
whether there are individuals who, after being bitten by infected
ticks, develop anti-Bb antibodies but show no symptoms possibly
associated with LB. Finally, we wished to determine whether the
number of spirochetes in infected ticks and the time elapsed before
tick removal were correlated to the development of LB.
2. Materials and methods
2.1. Study design
The study was initiated in the early summer of 2007 by
advertisement on local television and in the newspapers. Between
June 2007 and January 2008, the population served by nine
primary health care (PHC) centers in the County of O¨stergo¨tland in
the south-east of Sweden and the Department of Infectious
Diseases at the University Hospital in Linko¨ping (UHL) were asked
to participate in the study if they had been bitten by a tick. The
study subjects were asked to bring their tick(s) to their PHC center,
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Figure 1. Flow chart of the tick-bitten study subjects who pwhere they signed informed consent for study participation,
answered a standardized health questionnaire with relevant
questions, and provided a blood sample. Further, the participants
were asked to return to the PHC center for a second visit 3 months
later, for new blood sampling and to answer a second health
questionnaire. Two sets of blood samples, the ticks, and
questionnaires were sent to the UHL for processing and storage.
The study subjects could discontinue their participation at any
time, and samples would be discarded at the request of the
individual. The study was approved by the ethics committee of the
Faculty of Health Sciences at Linko¨ping University (Dnr.M132-06).
2.2. Questionnaires
The ﬁrst questionnaire included questions about the time of the
tick bite, estimated time of tick-exposure, and previous treatments
for Bb infection. The second questionnaire included questions
about new tick bites during the past 3 months, general health
condition during the period, symptoms possibly associated with
LB, andwhether or not they had attended their PHC center because
of the symptoms. The listed symptoms possibly associated with LB
were headache, fatigue, fever, neck pain, loss of appetite, nausea,
weight loss, vertigo, cognitive difﬁculties, radiating pain, myalgia/
arthralgia, and numbness. In addition, medical records were
obtained from study subjects who had attended health care for
symptoms possibly associatedwith LB, including erythemamigrans
(EM).
2.3. Inclusion and exclusion criteria
Individuals aged 18 years or older were recruited into the study
if they had recently been bitten by a tick and had brought it to the
ﬁrst PHC center visit, and had signed a consent to participate.
Individuals who were on antibiotic treatment during the time of
inclusion, who suffered from similar symptoms to those associated
with LB, or who were receiving treatment for diseases that would
require medications that could inﬂuence the immune response,
were not included in the study.
2.4. Study subjects
Three hundred and ninety-seven ticks were collected from 394
tick-bitten study subjects during the period June 2007 to January394 subjects 
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ects 
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excluded from further analysis due to: not attending the follow-
up visit in spite of having received a reminder (n = 46), suffering
from similar symptoms to those associated with LB at the time of
inclusion (n = 2), being on antibiotic treatment while included in
the study (n = 2), having blood samples that were not analyzed by
both ELISA assays (n = 2), and blood samples damaged during
transport (n = 1); 341 subjects completed the study. One of the
authors (PF), with clinical experience of LB over a long period of
time, scrutinized the medical records of study subjects who
attended health care for symptoms possibly associated with LB
during the study period, in order to determine current Bb
infection or symptoms resulting from or associated with other
diseases.
2.5. Analyses of Borrelia antibodies and seroconversion
On arrival at UHL, blood samples were centrifuged at 1250 g for
10 min at room temperature, and serum aliquots were frozen and
stored at 70 8C until further analysis. Serum samples from both
the time of tick bite and the second visit to the PHC center were
analyzed for both anti-ﬂagellum and anti-C6 antibodies. The
enzyme-linked immunosorbent assay (ELISA) IDEIATM Borrelia IgG
(Oxoid, Cambridge, UK) was used for the analysis of IgG antibodies
directed against the Bb ﬂagellum. The C6 Lyme ELISATM kit
(Immunetics Inc., Cambridge, MA, USA) was used for analysis of
IgM and IgG antibodies directed against the synthetic C6 peptide
derived from the Bb protein VlsE (variable major protein-like
sequence, expressed). A Bio-Rad CODA apparatus (Bio-Rad
Laboratories, Hercules, CA, USA) was used for the C6 analysis.
Both the ELISA assays were performed according to the manu-
facturers’ instructions with the exception of the IDEIATM Borrelia
IgG, in which single samples instead of duplicates were analyzed,
as is the standard procedure at the Department of Clinical
Microbiology, UHL. Seroconversion, i.e., the development of new
antibodies, indicating a current infection, was deﬁned as either a
change from seronegative to seropositive or a minimum two-fold
increase in arbitrary units (anti-ﬂagellum) or Lyme index (anti-C6
antibodies). All serum samples from study subjects who showed
seroconversion in any or both ELISAs were further analyzed with
the strip-immunoassay recomLine Borrelia IgG assay (Mikrogen,
Neuried, Germany) in order to conﬁrm the conversion. This detects
antibodies directed against p100 (B. afzelii), VlsE (fusion protein
from different genospecies), p58 (B. garinii), p41 (B. burgdorferi
sensu stricto), mp39 (B. afzelii), OspA (B. afzelii), OspC (B.
burgdorferi sensu stricto, B. afzelii, B. garinii, B. spielmanii), and
p18 (B. burgdorferi sensu stricto, B. afzelii, B. garinii 1, B. garinii 2, B.
spielmanii). The results and the occurrence of seroconversion from
the recomLine Borrelia IgG were interpreted according to the
manufacturer’s instructions. The serological assessment of a
current Bb infection, further deﬁned as subacute or asymptomatic,
was done by one of the authors (DN), who has extensive clinical
experience of LB in the hyperendemic A˚land Islands. Subjects, who
showed seroconversion in at least one of the ELISA assays veriﬁed
by seroconversion in the strip-immunoassay, were considered as
having a probable current Bb infection.
2.6. Handling of ticks
On arrival at UHL, the ticks were washed in 70% ethanol,
followed by washing with phosphate-buffered saline (PBS,
Medicago, Uppsala, Sweden). The ticks were then dried for a
few seconds on a paper towel and longitudinally bisected. The
bisected ticks were stored at20 8C before being subjected to DNA
extraction, followed by real-time PCR for the detection and
quantiﬁcation of Borrelia spp.2.7. PCR assays for detection, quantiﬁcation, and species
determination of Borrelia spp in ticks detached from humans
Detection and quantiﬁcation of Bb were performed using a real-
timePCRassay basedon the LightUponeXtensionTM (LUX) technique
(Invitrogen Corp.), as previously described by Wilhelmsson et al.22
The Bbwas detected and quantiﬁed using the group-speciﬁc primers
B16S_FL and B16S_R, targeting all Borrelia species so far detected in
Europe,22 covering a 131-base pair long, genus-speciﬁc region of the
16S rRNA gene. The primer pair was validated using DNA extracted
from strains of 11 different Borrelia species as well as DNA from
unrelatedbacterial species, humanDNA, andDNA fromticks. The PCR
products obtained were nucleotide sequenced in order to verify the
expected speciﬁcity. The results from the validation showed that the
primer pair possessed the expected speciﬁcity. Furthermore, the LUX
primer pairwas compared to an already published TaqMan real-time
PCRassay,23 showing that the LUX real-timePCRassaydetected three
more positive samples (out of a total of 399 DNA extracts from ticks
analyzed) than the TaqMan real-time PCR assay. The detection limit
for the LUX real-timePCRassaywas less than10gene copies,which is
equivalent to the number of copies that exists in oneBorrelia cell.23 In
addition, compared to the TaqMan assay, the LUX assay had a higher
mean efﬁciency.
The Bb-positive samples were further species determined by
two nested, conventional PCR assays, using primers targeting the
genetically diverse regions within the 5S–23S intergenic spacer
(IGS) and 16S–23S IGS. The outer primer pair used to amplify the
region of the 5S–23S IGS has previously been described by Postic
et al.24 and the inner primer pair has been reported by
Wilhelmsson et al.22 The primer set used to amplify the region
of the 16S–23S IGS has previously been described by Bunikis
et al.25 Macrogen Inc. (Seoul, Korea) performed the nucleotide
sequencing of the PCR products obtained from these two PCR
assays, based on BigDye chemistry.
2.8. Statistical methods
Fisher’s exact test was used to compare the percentage
distribution of data between the two groups of study subjects bitten
by Bb-infected and Bb-uninfected ticks. Age was assumed to be
normally distributed, and therefore the Student’s t-test was used to
compare the age distribution within the two groups of tick-bitten
study subjects. The Spearman rank correlation test was used to
calculate the correlation between the serology of the two ELISA
assays. All statistical calculations were done using SPSS 15.0 for
windows (SPSS Inc., Chicago, IL, USA). p-Values of< 0.05 were
considered signiﬁcant.
3. Results
A ﬂow-chart summarizing the results of the study is shown in
Figure 1.
3.1. Prevalence of Bb in the collected ticks
Seventy-ﬁve (19%) of the collected ticks were infected with Bb,
whereas the remaining ones did not contain any detectable levels
of the spirochetes.22 Sixty-four (19%) of the 341 tick-bitten study
subjectswho completed the study had been bitten by a Bb-infected
tick, while 277 (81%) study subjects had been bitten by a tick that
did not contain any detectable Bb spirochetes (Figure 1).
3.2. Few individuals seroconverted
Of the initial 341 blood samples, 136 (40%) had detectable levels
of anti-C6 antibodies and 39 (11%) samples had anti-ﬂagellum
L. Fryland et al. / International Journal of Infectious Diseases 15 (2011) e174–e181 e177antibodies, as expected in tick-exposed persons in an endemic
region. Of the 136 individuals who were seropositive for Bb
antibodies at the time of enrolment, 56 reported a past history of
symptomatic LB. C6 and ﬂagellum antibodies were correlated in
the serology (rho = 0.585, p < 0.01), i.e., positive detection of anti-
Bb antibodies in the ﬁrst blood sample. The test for antibodies to
native ﬂagellum protein showed signiﬁcantly less sensitivity (29%;
95% conﬁdence interval (CI) 22–37%), than the C6 antibody test
(p < 0.0001). Five of the 64 subjects (7.8%) who had been bitten by
a Bb-infected tick showed seroconversion for anti-ﬂagellum, anti-
C6, or both antibodies, as detected by ELISA during the 3 months
they participated in the study (subjects 1–5 in Table 1). In addition,
24 subjects among the 277 bitten by Bb-uninfected ticks (8.7%)
also showed seroconversion (subjects 6–29 in Table 1). The
samples from subjects displaying seroconversion in any of the
ELISA assays were further analyzed with a strip-immunoassay in
order to conﬁrm the ﬁnding. The seroconversion among the ﬁve
subjects bitten by Bb-infected ticks was veriﬁed by the develop-
ment of new antibodies in the strip-immunoassay in four of the
subjects. These four were consequently considered as having a
probable current Bb infection (subjects 1–4 in Table 1). Two of the
subjects who seroconverted had previously had LB, although not
within the year prior to participation in the study. Out of the 24
subjects bitten by Bb-uninfected ticks, and where seroconversionTable 1
Anti-Borrelia burgdorferi antibody serology and clinical manifestations in study subject
Anti-Bb antibody seroconversiona
Study
subject No.
Infected
tick
Anti-ﬂagellum, IgG Anti-C6, IgG/M
Sample I Sample II Sample I Sa
1 Yes + ++ + +
2 Yes  + + ++
3 Yes + ++ + +
4 Yes    +
5 Yes  + + +
6 No  +  +
7 No  +  +
8 No + ++ + +
9 No  + + ++
10 No  +  +
11 No  + + +
12 No   + ++
13 No  + + +
14 No    +
15 No    +
16 No  +  
17 No + ++ + +
18 No + ++ + +
19 No + ++ + +
20 No + ++ + +
21 No + ++ + +
22 No  + + +
23 No  + + +
24 No  + + +
25 No  + + +
26 No  + + +
27 No   + ++
28 No    +
29 No    +
Bb, Borrelia burgdorferi; P, probable; U, uncertain.
Serology results presented as: , anti-Bb antibody-negative; +, anti-Bb antibody-positiv
sera where anti-Bb antibodies against new antigens were detected. Positive ﬁndings in
a At least a two-fold increase in arbitrary units in the second blood sample or detec
b Visit to primary health care center.
c Clinically diagnosed erythema migrans.
d Fatigue.
e Myalgia/arthralgia.
f Vertigo.
g Neck pain.
h Headache.
i Numbness.was determined by at least one of the two ELISA assays, conversion
was veriﬁed by the strip-immunoassay in seven study subjects
(subjects 6–12 in Table 1).
3.3. Self-reported symptoms, need for medical attention, and Lyme
borreliosis diagnosis
Self-experienced symptoms possibly associated with LB were
reported by 91 tick-bitten subjects (Figure 2 and Table 2). Although
both study subjects bitten by infected and uninfected ticks
reported symptoms that may have been due to a current Bb
infection (Table 2), the frequency of subjects reporting symptoms
was higher in the group bitten by Bb-infected ticks (27/64)
compared to subjects bitten by uninfected ticks (64/277); 42% (95%
CI 30–54%) and 23% (95% CI 18–28%), respectively, p = 0.003
(Figure 2). There were no differences between subjects bitten by a
Bb-positive tick and subjects bitten by a Bb-negative tick when
comparing the frequency of reported experience of several
symptoms. Among the four subjects bitten by Bb-infected ticks
and considered as carrying a probable, current Bb infection, one
reported symptoms possibly associated with LB, but did not
attended a PHC during the study period for the reported symptoms
(subject 1 in Table 1). In contrast, two of the study subjects who
seroconverted after a bite by an uninfected tick, sought care fors showing seroconversion during the study period, n=29
Strip-Immunoassay, IgG Self-reported
symptoms
Current
Bb infection
mple II Sample I Sample II
+ ++ +d,e P
 +  P
+ ++  P
 +  P
   U
 + +f Yesb,c
+ ++ +d P
+ ++ +d,g P
 +  P
 +  P
+ ++  P
 +  P
+ + +d,f U
  +d,g,h,i U
  +e,g,h U
  +e Ub
+ +  U
+ +  U
+ +  U
+ +  U
+ +  U
+ +  U
+ +  U
+ +  U
+ +  U
   U
   U
   U
   U
e; ++, at least two-fold increase in anti-Bb antibody titer or, for Strip-Immunoassay,
bold-type.
tion of antibodies not found in the ﬁrst sample
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Figure 2. Pie chart showing the frequency of self-reported symptoms in study subjects bitten by Borrelia burgdorferi-positive (n = 64) and negative (n = 277) ticks. Ninety-
one of the 341 subjects in the study reported experience of symptoms possibly associated with Lyme borreliosis during the 3-month study period; 27 of these subjects had
been bitten by B. burgdorferi-infected ticks. Few of the subjects who had seroconverted experienced any symptoms possibly associated with Lyme borreliosis. Bb, Borrelia
burgdorferi sensu lato. (a) Subjects bitten by Bb-positive ticks; (b) subjects bitten by Bb-negative ticks.
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cases was diagnosed with an EM (subject 6 in Table 1).
3.4. Number of spirochetes in the ticks and time of tick exposure
Ticks from six of the 64 individuals bitten by Bb-positive ticks
were engorged (three adults and three nymphs) at the time of
collection (data not shown). Two study subjects who had been
bitten by two of the engorged adult ticks had seroconverted at the
3-month follow-up, but had not developed symptoms possibly
associated with LB. The other two study subjects who had
seroconverted were bitten by adult ticks that were not engorged.
Furthermore, among the four individuals considered as carrying a
probable current Bb infection, three had been bitten by ticks
containing high numbers of Bb (subjects 1, 2 and 4 in Figure 3),
whereas the tick collected from the fourth subject contained low
numbers of Bb spirochetes (individual 3 in Figure 3). Three of these
ticks contained B. afzelii, while the fourth subject’s tick contained B.
garinii, as reported elsewhere.22 The only one of the four
individuals who reported symptoms possibly associated with LB
had been bitten by a tick containing a high number of Bb
spirochetes (individual 1 in Figure 3). Estimated exposure to the
tick (the time from the bite until the tickwas removed) varied from
less than 1 min to 34 h, as reported by the subjects bitten by a Bb-
positive tick (data not shown). Among the four subjects considered
as having a probable current Bb infection, the individual bitten by
the tick with the lowest numbers of spirochetes reported the
shortest time of exposure (5 min; individual 3 in Figure 3). The
individual who reported symptoms estimated the time of exposure
to be almost 9 h (individual 1 in Figure 3). The other two subjects
reported exposure of less than 1 min and 6 h (the individual was
bitten by two ticks, of which one was negative for the detection ofTable 2
Self-reported symptoms in 341 tick-bitten study subjects
Frequency of different symptoms
All tick-bitten subjects (n=341)
No. of subjects reporting symptoms n=91
Reported symptoms (%)
Fatigue 18
Myalgia/arthralgia 17
Headache 14
Neck pain 11
Numbness 10
Vertigo 9
Concentration difﬁculties 5
Nausea 5
Radiating pain 4
Fever 3
Loss of appetite 2
Weight loss 2
a Several individuals reported more than one symptom. Erythema migrans was not iBb) and less than 16 h, respectively (individuals 2 and 4 in
Figure 3).
3.5. Additional tick bites during the study period
According to the questionnaires, 33 of the 64 (52%) study
subjects bitten by a Bb-positive tick reported that they had been
bitten by at least one more tick during the study period, whereas
139 of the 277 (50%) subjects bitten by a Bb-negative tick reported
additional tick bites.
3.6. Sex and age distribution in the tick-bitten groups
Morewomen thanmen participated in this study (63%women),
but no differences in sex distribution could be seen between the
group of study subjects bitten by Bb-infected ticks and those bitten
by uninfected ticks (64% and 63% women, respectively; data not
shown). The study subjects had a mean age of 62 years (range 19–
91), with women having a mean age of 61 years (range 19–84) and
men of 65 years (range 36–91) (data not shown). Study subjects
who showed seroconversion were older than those who did not
produce new antibodies (p = 0.029; data not shown).
4. Discussion
The main ﬁnding of this study was that only four out of 64
individuals (6%) bitten by a conﬁrmed Bb-infected tick showed
deﬁnite seroconversion for Bb antibodies 3 months after the tick
bite. Out of these four subjects considered to have a probable,
current Bb infection, only one reported experience of symptoms
possibly associated with LB, but had not attended a PHC for these
symptoms. Taken together, these results indicate that the risk ofreported by tick-bitten study subjectsa
Subjects bitten by a
Bb-infected tick (n=64)
Subjects bitten by a
Bb-uninfected tick (n=277)
n=27 n=64
17 19
16 17
15 14
13 10
9 10
10 7
6 5
6 5
3 5
0 4
4 1
1 3
ncluded in the list of symptoms in the questionnaire.
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Figure 3. Number of spirochetes in the ticks collected from tick-bitten study
subjects. The bars represent the number of Borrelia burgdorferi sensu lato
spirochetes in the collected B. burgdorferi-infected ticks. Black bars represent the
four of the 64 study subjects who had seroconverted, i.e., had at least a two-fold
increase in anti-B. burgdorferi antibodies as measured by ELISA and conﬁrmed by
the Strip-Immunoassay during the study period. One of the subjects experienced
symptoms possibly associated with Lyme borreliosis (patient 1). The ﬁfth bar
marked with an arrow represents the study subject with uncertain seroconversion.
(1) Seroconversion and symptoms (fatigue and myalgia/arthralgia); (2)
seroconversion; (3) seroconversion; (4) seroconversion; (5) uncertain
seroconversion.
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small, and furthermore, that the risk of developing clinical LB is
even smaller; they also show that asymptomatic Bb infection does
occur. Asymptomatic infections have previously been described in
studies screening for anti-Bb antibodies in blood donors10 and in a
vaccine trial,21 but not in a prospective study of tick-bitten
individuals like this.
The number of Bb spirochetes in the infected ticks varied
widely.22 Few of the subjects bitten by Bb-infected ticks had
serological evidence of a Bb infection and none developed clinical
LB, making this study too small to draw ﬁrm conclusions about
spirochete load in the tick and the risk of infection. However, the
majority of the study subjects reported that they had removed the
tickwithin 12 h. Experimental data have shown that the spirochete
is conﬁned to the lumen of the tick gut for 24 h after host
attachment26 and that the migration towards the salivary glands
starts approximately 36 h after the start of tick feeding.27 However,
one should keep in mind that the time of tick exposure was
estimated by the study subjects, and may therefore not be entirely
accurate. Interestingly, two of the study subjects bitten by Bb-
positive ticks and who seroconverted had been bitten by ticks that
were not engorged, suggesting that transmission may have
occurred early. However, previous studies have shown that
transmission during tick feeding may commence earlier in Ixodes
ricinus than in Ixodes scapularis.28,29 This may explain the
seroconversion in the subjects bitten by ticks that were not
engorged.
The frequency of Bb-infected ticks (19%)22 among those that
had bitten humans in this study is in accordance with a previous
Dutch study,16 where 20% of the ticks collected from patients
contained Bb DNA. Another study from Switzerland19 found a
lower frequency – 10% of the ticks collected from persons who
attended physicians concerning tick bites. However, both the
previous studies were designed to enroll tick-bitten individuals
who contacted general practitioners, which may have resulted in a
biased study group due to differences in anxiousness and concerns
about the risk of developing a disease in the persons involved. We
therefore chose to recruit study subjects by advertisement of a
scientiﬁc study, thereby achieving a more mixed study group with
a decreased risk of bias due to anxiousness. Furthermore, the
subjects were prospectively followed for 3 months.
Active/new production of antibodies was also found in seven
individuals bitten by ticks that did not contain detectable numbers
of Bb DNA, and one of them was clinically diagnosed with an EM.The new production of anti-Bb-speciﬁc antibodies is most
probably explained by the occurrence of other tick bites close to
the tick bite relevant to the study or of tick bites within the 3-
month study period. Two of the seven individuals reported that
they had been bitten by at least one more tick during the study
period. Another explanationmight be that these ticks contained Bb
spirochetes not detected by the PCR assay. Additional tick bites
were also reported by the four subjects who seroconverted after a
bite from Bb-infected ticks, and we can thus not be sure that Bb
was transmitted by the tick we analyzed. However, since we used
stringent criteria for current Bb infection, i.e., an infection during
the study period, the conclusions from this study regarding the risk
of developing LB after a bite by a Bb-infected tick and the
occurrence of asymptomatic Bb infection still holds true, even if Bb
was transmitted by another tick. In fact, if Bb was transmitted by
another tick, the risk of developing LB after a single tick bite is even
smaller, since thismeans that the tick included in this study did not
transfer the spirochetes despite being infected.
Bb infection is traditionally diagnosed mainly by the appear-
ance of clinical manifestations and by serology.30 However, the
serology-based diagnostics are complicated, since there is no ‘gold
standard’method and serology is negative for severalweeks during
the early stage of infection. There are many commercial kits
available for detecting IgM and/or IgG antibodies against different
native, synthetic, or recombinant Bb antigens.30 The background
seropositivity level of the population used as control group is also
of importance in relation to the speciﬁcity of an antibody test.
Second-stage tests with immunoblot are not widely used in
Sweden. In order to ensure sensitivity as well as speciﬁcity we
instead used two different commercial ELISA assays, which detect
antibodies against different Bb antigens, followed by strip-
immunoassay analyses of samples from subjects showing sero-
conversion in either of the ELISA tests. Both the anti-ﬂagellum and
the anti-C6 assays used in this study have previously been shown
to perform at least as well as other commercial assays for detecting
anti-Bb antibodies.31–34 Furthermore, both Philipp et al. and
Tjernberg et al., have shown that the detection of anti-C6
antibodies correlates well with ongoing LB both in experimental
animals35 and in humans.35,36 However, the level of C6 antibodies
after treatment can neither be used as an indicator of treatment
success, nor of active disease.37 The anti-ﬂagellum assay is
routinely used for the clinical diagnosis of LB at UHL, and the
anti-C6 assay is used clinically at A˚land Central Hospital. In order to
ensure speciﬁcity, sera from all subjects showing seroconversion in
one or both of the ELISA assays were further analyzed by the strip-
immunoassay, detecting antibodies against 15 different Bb
antigens from different Bb species. However, since we were
interested in the seroconversion and not the seroprevalence in the
study group, we did not use the strip-immunoassay for those
subjects whowere seropositive but did not increase their antibody
titers over the study. Only subjects in which seroconversion was
conﬁrmed by the strip-immunoassay were considered to have a
probable current Bb infection, which most likely ensures the
speciﬁcity of the study, i.e., that the subjects we deﬁned as having a
Bb infection were actually infected. The frequency of repeated tick
bites and the background seroprevalence were surprisingly high,
considering that the county of O¨stergo¨tland has not previously
been considered as an endemic area. We previously reported a Bb
infection prevalence of 5.8% among healthy blood donors in a study
conducted in an inland town district in the county of O¨stergo¨t-
land.10 One possible explanation for the increased seroprevalence
in the current study might be that this was not limited only to the
previous inland district, but also included several other parts of the
county with different geographical locations, in order to better
cover areas with increased risk of tick exposure. In addition, the
anti-ﬂagellum ELISA test for the detection of Bb antibodies used in
L. Fryland et al. / International Journal of Infectious Diseases 15 (2011) e174–e181e180the ﬁrst study is routinely used by the health care centers in the
county of O¨stergo¨tland. The anti-C6 ELISA, however, has to our
knowledge, not been used either by the health care services or for
seroprevalence studies in the county of O¨stergo¨tland. Therefore,
the surprisingly high seroprevalence found, especially with the
anti-C6 assay may be due to differences in sensitivity between the
two different tests.
The symptoms associated with LB are mainly non-speciﬁc and
frequent in the general population. In the current study, although
the frequency of subjects experiencing symptoms was increased
among subjects bitten by Bb-positive ticks, the total number of
reported symptoms was similar in both groups. This supports the
ﬁndings of a previous study by Cerar et al.,38 who reported
signiﬁcant symptomatology in normal non-Borrelia-infected
clinical subjects in Slovenia.
The current data indicate an age difference between individuals
concerning seroconversion, with higher age in the group of study
subjects who seroconverted after being bitten by a Bb-infected
tick. This ﬁnding may be explained by a weakening of the innate
immune response with age,39,40 resulting in an infection that is not
cleared before the adaptive response is activated. Another
explanation may be the age-related increase in certain subclasses
of immunoglobulins due to cumulative exposure to antigens over
time.41,42
In conclusion, this study shows that the risk of developing LB
after a tick bite by a documented Bb-infected tick is small.
Furthermore, asymptomatic Bb infection, documented by sero-
conversion in the absence of symptoms possibly associated with
LB, appears to be frequent among individuals who become
infected.
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